Oxford Immunotec Global PLC (OXFD)
(Delayed Data from NSDQ)
$16.54 USD
+0.35 (2.16%)
Updated May 3, 2019 04:00 PM ET
After-Market: $16.55 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.54 USD
+0.35 (2.16%)
Updated May 3, 2019 04:00 PM ET
After-Market: $16.55 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Oxford Immunotec (OXFD) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Oxford Immunotec (OXFD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oxford Immunotec (OXFD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 50.00% and 4.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Oxford Immunotec (OXFD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -428.57% and -4.19%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Oxford Immunotec (OXFD) Q2 Earnings Expected to Decline
by Zacks Equity Research
Oxford Immunotec (OXFD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oxford Immunotec (OXFD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -185.71% and -1.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Oxford Immunotec (OXFD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 45.45% and 4.80%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Oxford Immunotec Global Stock: Moving Average Crossover Alert
by Zacks Equity Research
Oxford Immunotec Global is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
MEDNAX (MD) Ties Up With Homestead to Expand in Florida
by Zacks Equity Research
MEDNAX (MD) collaborates with Associated Pediatricians of Homestead to provide clinical services and expand presence in Florida.
Oxford Immunotec (OXFD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 180.00% and 4.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Oxford Immunotec (OXFD) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Oxford Immunotec (OXFD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oxford Immunotec (OXFD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 140.00% and 0.76%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Oxford Immunotec (OXFD) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Oxford Immunotec (OXFD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Varian (VAR) Installs ProBeam Compact in Thailand's Hospital
by Zacks Equity Research
Varian (VAR) gains from a slew of recent developments in its Proton Therapy platform.
Varian (VAR) to Boost Cancer Treatment With New Partnership
by Zacks Equity Research
Varian (VAR) expects to enhance cancer care with the new collaboration with IAEA, which is likely to drive Varian's core Oncology business.
Here's Why You Should Invest in Wright Medical Stock Now
by Zacks Equity Research
Wright Medical (WMGI) continues to benefit from strong international sales, new product launches and solid prospects in the global Orthopedic space.
Here's Why You Should Invest in CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.
Luminex (LMNX) Presents ARIES MRSA Assay to FDA for Clearance
by Zacks Equity Research
Luminex (LMNX) submits the ARIES MRSA assay to the FDA for clearance. The company's ARIES system will get a substantial boost once the FDA clearance is through.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, severe rivalry is a lingering woe.
Here's Why You Should Retain Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.
Here's Why You Should Hold on to McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market.
Here's Why You Should Retain Allscripts (MDRX) Stock Now
by Zacks Equity Research
Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.
Here's Why You Should Invest in Cooper Companies Stock Now
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker (SYK) is gaining steadily from strong international growth and robust product portfolio. However, unfavorable pricing environment remains a woe.
AMN Healthcare (AMN) Closes Advanced Medical Acquisition
by Zacks Equity Research
AMN Healthcare (AMN) completes Advanced Medical buyout that will help the former to boost offerings in some of the fastest growing and very important care settings.